Navigation Links
Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
Date:9/24/2009

n a number of malignancies including colon cancer and is targeted for entry into clinical trials in 2012, fulfilling our goal of entering one new ACI into the clinic each year for the next three years.

About PROVENGE

PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of ACIs specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Dendreon recently announced that the pivotal Phase 3 IMPACT study of PROVENGE in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control.

Webcast Replay Information

If you are interested in listening to the replay of the analyst day webcast, you may access it from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
3. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
4. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
7. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
8. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... JOSE, Calif. , Oct. 1, 2014  SI-BONE, Inc., ... iFuse Implant System, ® a minimally invasive surgical (MIS) ... (SI) joint, today announced the expansion of its European operations ... Mr. Eric Schaber as General Manager, Germany.  Mr. ... currently vice president of Europe , ...
(Date:10/1/2014)... Switzerland , October 1, 2014 ... and Next Generation Sequencing (NGS) data analysis, today launches ... full cystic fibrosis analysis in a single NGS experiment. ... of all types of variants in a single NGS ... now, it has not been possible to simultaneously analyse ...
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... MacMillan , Hologic,s President and Chief Executive Officer, will ... on October 1, the first day of Breast Cancer ... the Company,s campaign focused on the important benefits of ... by the FDA as clinically superior to traditional mammography. ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... Water Street Healthcare Partners , a strategic private ... announced today that it has completed a sale and ... CareCentrix is the nation,s leading provider of ... industry.  Water Street sold its majority interest in CareCentrix ...
... COPENHAGEN, Denmark and LAGUNA NIGUEL, Calif., Sept. 20, ... today announced that the two companies have entered ... manufacture of bulk IB1001, Inspiration,s intravenous recombinant factor ... of bleeding in individuals with hemophilia B. Under ...
Cached Medicine Technology:Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix 2Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix 3CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 2CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 3
(Date:10/1/2014)... Engineering and Physical Sciences Research Council (EPSRC) will ... industrial control systems which run, for example, manufacturing ... rail network. , The research will help ... infiltrating the systems behind our critical national infrastructure. ... Control Systems (RITICS), based at Imperial College London, ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... The U.S. Food and Drug Administration (FDA) has decided ... (R) (infliximab) to be used in the treatment of ... today. Crohn's disease affects the gastrointestinal tract and causes ... now there is no drug to treat children who ...
... Illinois at Chicago in collaboration with their colleagues from ... enzyme in the virus that causes SARS//, severe acute ... in the March 27 issue of the Proceedings of ... form a new drug target for drug makers. ...
... the cause of four men whose lives took a turn ... German company// TeGenero and medical research company Parexel, has received ... handling the case, has felt ignored after receiving no response ... conducted at Northwick Park Hospital in Harrow, north-west London, last ...
... It is already known to us that some popular spices ... Liu, an assistant professor of obstetrics// and gynecology at the ... powder dissolved in solution by putting it on ovarian cancer ... that ginger can kill ovarian cancer cells. But the study ...
... Harris Interactive? for the Vagisil Women's Health CenterSM conducted a ... of today's American women are taking active roles in their ... thirds of women aged 18 and older (63 percent) report ... go to a gynecologist, 61 percent say they "always" go ...
... the risk of coronary heart attack and could in general be ... study of 4,400 men and women aged 65 and over by ... a link between the amount of alcohol drunk and the likelihood ... ,People who drink 14 or more glasses of wine or ...
Cached Medicine News:Health News:FDA Accords Priority Review For Pediatric Crohn's Disease Drug 2Health News:Spices Could Be Employed To Treat Certain Cancers 2Health News:Women aware of “feminine health” : their attitud 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: